Anaplastic thyroid carcinoma (ATC) is considered one of the most aggressive malignancies, having a poor prognosis and being refractory to conventional chemotherapy and radiotherapy. Alteration in histone deacetylase (HDAC) activity has been reported in cancer, thus encouraging the development of HDAC inhibitors, whose antitumor action has been shown in both solid and hematological malignancies. However, the molecular basis for their tumor selectivity is unknown. To find an innovative therapy for the treatment of ATCs, we studied the effects of deacetylase inhibitors on thyroid tumorigenesis models. We show that HDACs 1 and 2 are overexpressed in ATCs compared with normal cells or benign tumors and that HDAC inhibitors induce apoptosis selectively in the fully transformed thyroid cells. Our results indicate that these phenomena are mediated by a novel action of HDAC inhibitors that reduces tumor necrosis factor-related apoptosis-inducing ligand protein degradation by affecting the ubiquitin-dependent pathway. Indeed, the combined treatment with HDAC and proteasome inhibitors results in synergistic apoptosis. These results strongly encourage the preclinical application of the combination deacetylaseproteasome inhibitors for the treatment of ATC.
Introduction
Thyroid carcinoma of follicular cell origin is the most common endocrine malignancy, with an estimated 25 000 new cases diagnosed annually in the United
States. The prognosis of thyroid carcinoma varies from the indolent well-differentiated papillary and follicular thyroid carcinomas, with a 30-year mortality rate of approximately 6%, to poorly differentiated thyroid carcinoma, which has a 60% 5-year survival rate, to anaplastic thyroid carcinoma (ATC), which is very aggressive and always fatal in a few months (Saltman et al., 2006) . Surgical resection and radioactive iodine can be an effective treatment only for well-differentiated tumors. Conversely, ATC is refractory to conventional treatment as chemo-and radiotherapy, therefore representing an excellent target for innovative therapies.
In eukaryotes, genomic DNA is wrapped around histone octamers and the amino-terminal lysine residues of histone tails can be modified by acetylation, methylation and ubiquitination (Jenuwein and Allis, 2001) . The balance between the acetylated and deacetylated states of chromatin is regulated by the histone acetyltransferase (HAT) and histone deacetylase (HDAC) enzymes (Marks et al., 2001; Kelly and Marks, 2005; Minucci and Pelicci, 2006) . In fact, histone acetylation results in an opening of the chromatin fiber, whereas histone deacetylation causes a condensation of chromatin, preventing transcription factor accessibility and function. Mammalian HDACs are divided into four classes: (a) class I includes HDACs 1, 2, 3 and 8; (b) class II includes HDACs 4, 5, 6, 7, 9 and 10; (c) class III HDACs are the sirtuins (SIRT1-7); and (d) class IV contains HDAC 11 (Gallinari et al, 2007; Mai and Altucci, 2009; Altucci and Stunnenberg, 2009) .
Aberrant regulation of gene expression attributed to alterations in histone acetyltransferase or HDAC recruitment and activity has constantly been found in both solid and hematologic tumors (Marks et al., 2001; Minucci and Pelicci, 2006; Mai and Altucci, 2009) . Therefore, HDACs can be considered potential therapeutic targets for the treatment of human malignancies. There are at least five distinct classes of HDAC inhibitors (HDACis): short-chain fatty acids such as butyric acid, hydroxamic acids such as SAHA (suberoylanilide hydroxamic acid), electrophilic ketones, benzamides such as MS-275 (Hess-Stumpp et al., 2007) and cyclic peptides such as depsipeptide FK-228. HDACis induce growth arrest, differentiation and apoptosis of cancer cells in vitro and in vivo tumorbearing animal models (Gallinari et al., 2007; Xu et al., 2007) . HDACis have antitumor activity against different cancers at doses that are well tolerated by patients, and SAHA (Vorinostat, Zolinza) was approved quite recently by the US FDA for the treatment of cutaneous manifestations in patients with advanced, refractory cutaneous T-cell lymphoma (Duvic and Vu, 2007; Mann et al., 2007) . The aim of our work has been to evaluate the possibility of an innovative therapy for ATC based on HDACis, investigating the effects and mechanisms of action of some HDACis on a model of rat thyroid cells transformed by the v-ras-Ki oncogene, which is one of the most common genetic lesions found in human tumors. We have chosen SAHA and MS-275, two HDACis in clinical trial, for the treatment of different types of tumors Kummar et al., 2007; Blumenschein et al., 2008; Garcia-Manero et al., 2008; Gore et al., 2008) . SAHA inhibits both class I and II HDACs, whereas MS-275 is more selective inhibiting mostly HDACs 1 and 2. This difference is of great importance in understanding the role of HDAC enzymes and their inhibitions in thyroid cancer.
We first show that HDACs 1 and 2 are overexpressed in the anaplastic thyroid cancer tissues compared with normal thyroid tissues, and in the human and rat thyroid cancer cells with respect to the normal ones. Subsequently, we show that both HDACis induce apoptosis selectively in the FRTL-5 v-ras-Ki rat thyroid transformed cells, but not in the normal thyroid FRTL-5 Cl2 cells. The stabilization of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein with its consequent accumulation in the cancer cells (i) accounts for the apoptotic effect of the HDACis, (ii) represents a novel mechanism for TRAIL-mediated apoptosis and (iii) is linked to the inhibition of HDACs 1 and 2.
Results
HDAC expression in human thyroid tumor biopsies and in rat thyroid cell lines First, we evaluated the HDACs 1, 2 and 3 protein levels in normal thyroid, and in papillary, follicular and anaplastic thyroid carcinomas by immunohistochemistry. HDAC 1 and 2 proteins were found highly overexpressed in ATC samples compared with normal thyroid tissue ( Figure 1a) . The immunohistochemical results are summarized in Figure 1b . An intense nuclear staining for HDAC1 (Figure 1a , sub-panel 2) and HDAC2 ( Figure 1a , subpanel 4) was observed in the ATCs, whereas only a slight increase and weak nuclear staining was observed in papillary thyroid carcinomas and follicular thyroid carcinomas (data not shown) with respect to normal thyroid ( Figure 1a , sub-panels 1 and 3). Conversely, HDAC1 and HDAC2 staining was comparable in thyroid adenomas, goiters and normal tissues (data not shown). HDAC3 staining did not show significant differences in ATCs compared with normal thyroid tissue (data not shown). Thus, the increase in HDACs 1 and 2 expression correlates positively with malignancy.
Subsequently, we analysed class I HDAC expression in rat thyroid cell lines transformed with different oncogenes and in human ATC cell lines with respect to the normal counterpart. The characteristics of the rat cell lines used are summarized in Table 1 . HDAC1 protein levels were higher in tumorigenic cells (FRTL-5 v-ras-Ki and PC E1A þ v-raf) and lower in nontumorigenic cells (PC v-ras-Ki) than in normal ones (FRTL-5 Cl2 and PC Cl3) (Figure 1c ). HDAC2 protein was more abundant in FRTL-5 v-ras-Ki than in FRTL-5 Cl2. No significant differences in HDAC3 expression levels between normal and transformed cells were observed (Figure 1c) . Analogous results were obtained in human ATC cell lines (FRO, FB1, 8505C, ACT-1) compared with normal primary thyroid cultures (Figure 1c ). The expression of the specific HDACs 1 and 2 mRNA in rat thyroid cell lines, analysed by RNase protection assay, essentially supported the data on protein levels indicating that the expression of class I HDACs is regulated at the transcriptional level and that HDACs 1 and 2 are overexpressed in malignant thyroid cells (Figure 1d ).
The HDACis, SAHA and MS-275, induce growth arrest and apoptosis in v-ras-Ki transformed rat thyroid cells To test whether the overexpression of HDACs 1 and 2 corresponds to the increased effect of HDACis in tumor thyroid cells, we treated normal (FRTL-5 Cl2 and PC Cl3) and transformed (FRTL-5 v-ras-Ki and PC v-rasKi) rat thyroid cell lines with 5 mM SAHA and 5 mM MS-275 for 24, 48 and 72 h. We have chosen these concentrations as they have shown the optimal ones for inducing the accumulation of histone acetylation in cell cultures (Mitsiades et al., 2005) . Fluorescence-activated cell sorting (FACS) analysis in Figure 2 shows that both SAHA and MS-275 induced apoptosis preferentially in the transformed cell lines, therefore confirming the HDAC expression data. The apoptotic effect was more evident in the highly tumorigenic cell line FRTL-5 v-rasKi (Figure 2b ) than in PC v-ras-Ki, which did not show a malignant phenotype (Figure 2c ), thus suggesting that HDACis might be more efficient in highly malignant thyroid tumors. Normal cell lines FRTL-5 Cl2 and PC Cl3 (Figure 2a ) did not show any apoptotic effect after treatment. In full agreement with these findings, caspase-3 as effector caspase, casp-8, -9 initiator activities, in the HDACi-treated cells were activated in FRTL-5 v-ras-Ki but not in FRTL-5 Cl2 (Figure 2d ), thus indicating that caspase-dependent apoptosis mediates cell death in transformed cells but not in normal thyroid cells. Caspase activation is also detectable after brief time of exposure to HDACis (Supplementary Figure 1) .
In a similar experimental setting, the cell cycle analysis did not show significant differences between normal and tumor cell lines (Figures 3a and b) . In fact, both cell lines undergo cell cycle arrest in the G1 phase after SAHA and MS-275 treatment, and the percentage of arrested cells increases with the time of exposure to both drugs (Figures 3a and b) . Moreover, neither SAHA nor MS-275 vehicles (dimethylsulfoxide and ethanol, respectively) affected cell cycle or apoptosis of the analysed cell lines at the concentration used (Figures 2  and 3) . Furthermore, the evaluation of histone H3 acetylation by western blot analysis (Figure 3c ) did not display significant differences of acetylated histone regulation among FRTL-5 Cl2 and their tumoral ras version. Indeed, we could detect an increase of H3 acetylation and a cell cycle arrest in both normal and cancer cells.
Interestingly, the compound MC1568, which is known to inhibit only class II HDACs ( Figure 3 , single knockdown of either HDAC1 or HDAC2 caused a reduction of about 50% in the number of SAHA-induced apoptotic cells, whereas double knockdown caused a reduction of about 70% in the number of SAHA-induced apoptotic cells. Therefore, these results indicate that the apoptotic effect of SAHA is attributed to the inhibition of HDAC1 and HDAC2 activity. Finally, to evaluate the extent of SAHA and MS-275 effects in these thyroid cell lines, we treated FRTL-5 Cl2 and FRTL-5 v-ras-Ki cell lines for 24, 48 and 72 h, removing the drugs and allowing the cells to grow for an additional 24 and 48 h. As shown in Figure 3d , FRTL-5 Cl2 re-entered the S phase after drug removal, whereas FRTL-5 v-ras-Ki treated for 72 h, but not those treated for 24 and 48 h (data not shown), remained blocked in the G1 phase going toward death. These results corroborate the low toxicity of SAHA and MS-275 for normal thyroid cells, thus stressing the selectively induced cell death caused by HDACis in transformed cells.
SAHA and MS-275 induce TRAIL in transformed FRTL-5 v-ras-Ki thyroid cells
To understand the molecular events occurring upon HDACi treatment and underlying selective tumor cell death, we evaluated the levels of known proteins involved in apoptosis such as Bax, Bcl2 and BclxL in both FRTL-5 Cl2 and FRTL-5 v-ras-Ki before and after treatment. The treatment with both HDACis did not affect the protein levels of Bax and Bcl2, whereas BclxL was upregulated in normal cells and downregulated in cancer cells (Supplementary Figure 4) . High levels of BclxL could be important in blocking the apoptotic process in normal cells. When cell cycle-related proteins were investigated, p21/WAF1 was induced only by MS-275 in both normal and transformed cells after 16 h of treatment, whereas p27/Kip1 was induced by both drugs only in normal cells. Therefore, it is reasonable to speculate that p27 induction might be responsible for the cell cycle arrest caused by these HDACis in normal thyroid cells.
Tumor necrosis factor-related apoptosis-inducing ligand (TNFSF10, tumor necrosis factor ligand superfamily member 10) is a member of the tumor necrosis factor cytokine family that induces apoptosis on binding to its death receptors TRAIL receptor 1 (death receptor 4, DR4) and TRAIL receptor 2 (death receptor 5, DR5) (Johnstone et al., 2008) . The tumor-selective action of HDACis has been shown to be mediated mainly by the proapoptotic ligand TRAIL, which is induced at the transcriptional level only in transformed cells Earel et al., 2006; Hall and Cleveland, 2007; Johnstone et al., 2008; Macher-Goeppinger et al., 2009) . TRAIL preferentially kills transformed but not normal cells, both in vitro and in vivo, and the mechanisms for this selectivity are presently obscure (Ashkenazi, 2002; Mahalingam et al., 2009) .
Therefore, we analysed TRAIL expression by western blot in normal and transformed cells. As shown in Figure 4a (top), both SAHA and MS-275 induced TRAIL protein only in FRTL-5 v-ras-Ki cells. We also confirmed this result evaluating surface TRAIL protein levels by FACS (Figure 4a No tumors appeared after injection of 2 Â 10 6 cells into six athymic mice. b Tumors appeared at least 3 weeks after injection of 2 Â 10 6 cells into athymic mice. c Tumors appeared not later than 10 days after injection of 2 Â 10 6 cells into athymic mice. Figure 4) . To confirm that TRAIL is stabilized by HDACis, we analysed the half-life of TRAIL in FRTL-5 v-ras-Ki treated with 5 mM SAHA for 24 h and 5 mg/ml cycloheximide for 2, 4 and 8 h to block mRNA translation. As shown in Figure 5c , TRAIL protein disappeared after 8 h in FRTL-5 v-ras-Ki treated only with cycloheximide, whereas it was still present after 8 h in cycloheximide-SAHA-treated cells, indicating that SAHA treatment induces an increase of the TRAIL protein half-life.
HDAC inhibitors in thyroid carcinomas
To further show that SAHA reduces TRAIL protein degradation affecting the ubiquitin-dependent pathway, we co-transfected FRTL-5 v-ras-Ki cells with pEGFP-N1 and p-Ubi-His or with pEGFP-TRAIL and p-UbiHis plasmids. We determined the degradation of the TRAIL-GFP fusion protein by evaluating cell fluorescence by FACS after treatment with 5 mM SAHA for 16 h. The amount of exogenous TRAIL, proportional to the cell fluorescence, increased after treatment with SAHA, whereas it was reduced after overexpression of ubiquitin (Figure 6a ). Taken together, these results indicate that SAHA reduces TRAIL degradation in thyroid-transformed cells by altering the ubiquitindependent pathway of degradation. We performed an immunoprecipitation experiment to investigate whether TRAIL can be ubiquitinated. Then, we treated FRTL-5 v-ras-Ki with SAHA for 24 h and immunoprecipitated cell lysates with a mouse monoclonal anti-ubiquitin antibody. Subsequently, ubiquitinated TRAIL protein was detected by western blot analysis using an anti-TRAIL antibody. As shown in Figure 6b , we were able to detect a band of B72 kDa that is attributed to TRAIL protein (33 kDa) bound to 4-5 ubiquitin molecules (B8 kDa). This result confirms that TRAIL protein is a target of the ubiquitin-proteasome pathway. In agreement with our finding that SAHA stabilizes TRAIL protein, the amount of ubiquitinated TRAIL is lower in SAHA-treated cells with respect to vehicletreated cells (Figure 6b ). However, it is possible that SAHA could reduce the TRAIL protein degradation also affecting the ubiquitin-proteasome pathway downstream of the ubiquitination event. Finally, to show that our findings can also be extended to human anaplastic cells and serve as an alternative therapy for thyroid anaplastic cancer, we verified the efficacy of the combination MG132 þ SAHA on FRO, a human anaplastic thyroid cell line. We treated the FRO cells (Fagin et al., 1993) with 5 mM SAHA, 0.25 mM MG132 or with the combination of both drugs. Although the single treatments did not induce cell cycle arrest (Supplementary Figure 9a ), the combination SAHA þ MG132 had a synergistic effect in inducing apoptosis in FRO cells as previously shown for FRTL-5 v-ras-Ki cells (Figure 5c ). Indeed, the combined treatment caused an evident increase in apoptosis compared with the single treatments (Supplementary Figure 9b) . Analogous results were obtained for FB1 ( Supplementary Figure 9c and d), another human anaplastic thyroid cell line (Fiore et al., 1997) , thus suggesting that this combination treatment might be useful against anaplastic thyroid cancer.
Discussion
In this study, we have analysed the effects of two potent HDACis, namely SAHA (Vorinostat, Zolinza) and MS-275, in a well-defined cell system where the process of tumor transformation is well known, allowing a better comprehension of the mechanisms through which these drugs may act. The cell system studied here is represented by the rat thyroid cells infected with the Kirsten murine sarcoma virus carrying the v-ras-Ki oncogene (Fusco et al., 1987) . These cells have lost the expression of the typical markers of thyroid differentiation, grow with a high efficiency in soft agar and induce tumors after injection into athymic mice. The critical role of ras gene activation in some thyroid cancer histotypes was confirmed by the induction of thyroid follicular carcinomas associated with lung metastasis following the injection of the Kirsten murine sarcoma virus into the thyroid gland of adult Fischer rats (Portella et al., 1989) . The important role of ras oncogene in thyroid cancer was also shown in human follicular and anaplastic carcinoma in which the frequency of mutation in this gene is about 50% (Nikiforova et al., 2003) .
SAHA and MS-275 have a different spectrum of action, as SAHA inhibits both class I and II HDACs, whereas MS-275 inhibits only HDACs 1, 2 and 3 to a lower extent. They are already objects of clinical trials for the treatment of solid and hematological tumors with minor side effects (Glaser, 2007; Mai and Altucci, 2009) . SAHA (Vorinostat, Zolinza) in particular has been approved by the Food and Drug Administration for the treatment of cutaneous manifestations of T-cell lymphoma in cancer patients. Previous studies have shown that SAHA arrests cell growth, induces apoptosis of a wide variety of transformed cells and inhibits tumor growth in animal models bearing solid tumors and hematological malignancies (Marks, 2007) . Indeed, SAHA and MS-275 display antitumor activity in acute myeloid leukemia mediated by both p21/WAF1 and the tumor-selective death ligand TRAIL (Altucci et al., 2005; Insinga et al., 2005; Nebbioso et al., 2005) .
In this study, we show that both SAHA and MS-275 induce apoptosis in rat thyroid-transformed cells with highly malignant phenotype, but not in normal cells. The increase in the activities of caspases-8 and -9, induced by the treatment with these drugs, suggested that both SAHA and MS-275 could activate mitochondrial and death receptor apoptotic pathways. However, we obtained a decrease in HDACi-mediated apoptosis by the silencing TRAIL expression, thus indicating that TRAIL is a key mediator of HDACi-induced apoptosis in thyroid carcinoma cells. The absence of significant differences in TRAIL transcript levels in both normal and transformed cells suggested TRAIL regulation at the protein level. This hypothesis appears to be confirmed by (i) the synergistic apoptotic effect of SAHA and the proteasome inhibitor MG132; (ii) the proportional increase in TRAIL protein level in the combo treatment with respect to the single one; and (iii) the clear increase in TRAIL half-life induced by SAHA.
The ubiquitination of TRAIL, reported here for the first time, represents an important mechanism for the regulation of the TRAIL protein level and may suggest new approaches to a better induction of its stabilization. Therefore, our results suggest a new molecular mechanism by which HDACis regulate cell death through a ubiquitin-proteasome-dependent stabilization of TRAIL. Our demonstration that (i) TRAIL is degraded through a ubiquitin-proteasome pathway and (ii) SAHA stabilizes TRAIL protein by reducing its ubiquitination and proteasome degradation is a fully novel finding that explains, at the molecular level, why the combination of a proteasome inhibitor and an HDACi might be successful in the treatment of anaplastic thyroid cancers. The efficacy of HDACis on human thyroid carcinoma cell lines has already been reported (Mitsiades et al., 2005) . However, on the basis of the proteasomedependent TRAIL stabilization, our results unveil the mechanism by which the HDACi selectively kill cancer cells. Moreover, we show that the combination of HDACi with a proteasome inhibitor has a much higher efficacy, with respect to the treatment with HDACi alone, inducing the death of cell lines deriving from ATCs. In agreement with our findings, the synergism of proteasome inhibitors with HDACis has recently been reported in glioma, in cervical cancer and in leukemia (Miller et al., 2007 (Miller et al., , 2009 Dai et al., 2008; Yu et al., 2008; Lin et al., 2009) , strongly supporting our molecular model and suggesting the application of this combined treatment in other types of cancers.
Therefore, the synergism between MG132 and SAHA, through TRAIL signaling pathway activation, encourages the preclinical application of the combination of HDACis with proteasome inhibitors such as Bortezomib, or with drugs activating the TRAIL apoptotic pathway. In conclusion, our findings may contribute to the development of a novel, molecularly based approach in thyroid cancer treatment.
Materials and methods
Cell lines FRTL-5 Cl2, PC Cl3, FRTL-5 v-ras-Ki and PC v-ras-Ki are rat thyroid epithelial cell lines. Rat and human thyroid cell lines were described previously (Fusco et al., 1987; Fagin et al., 1993; Fiore et al., 1997; Pallante et al., 2005; Nappi et al., 2009) .
Chemicals MS-275 (a kind gift from Bayer-Schering, Berlin, Germany) and MG132 (Calbiochem, Nottingham, UK) were dissolved in ethanol, whereas SAHA (Alexis, Florence, Italy) and MC1568 were dissolved in dimethylsulfoxide.
Apoptosis and cell cycle
Normal and transformed rat thyroid cell lines were treated with 5 mM SAHA, 5 mM MS-275 and 5 mM MC1568 for 24, 48 and 72 h. Apoptosis was quantified by propidium iodide-Annexin-V double staining (Altucci et al., 2001) . The apoptotic cells Annexin V-positive/propidium iodide-negative were considered. Recycling experiments: after treatment of the cells, the medium was replaced with fresh medium and the cells remained in culture for an additional 24 and 48 h. Samples were acquired on an FACS-Calibur flow cytometer using the Cell Quest software (Becton Dickinson, Milan, Italy) and analysed by standard procedures using the same software and the ModFit LT version 3 Software (Verity, Topsham, ME, USA) as previously reported Scognamiglio et al., 2008) .
Caspase assay FRTL-5 Cl2 and FRTL-5 v-ras-Ki were treated with 5 mM SAHA and 5 mM MS-275 for 8, 16 and 24 h. Caspases-3, -9 and -8 activities were measured by FACS following the manufacturer's instructions (B-Bridge, Mountain View, CA, USA) (Bontempo et al., 2007) .
RNase protection assay and RT-PCR
The ribonuclease (RNase) Protection Assay was performed according to standard procedures (Pharmingen, San Diego, CA, USA) as previously reported (Altucci et al., 2001; Scognamiglio et al., 2008) . Probes used for specific HDAC detection in rats are available on request. FRTL-5 Cl2 and FRTL-5 v-ras-Ki RNA have been used for RT-PCR according to the manufacturer's instructions (Qiagen, Milan, Italy) . Quantitative RT-PCR was performed as previously described (Pallante et al., 2008) . Primer sequences are available as Supplementary Materials and methods.
RNA interference
See Supplementary Materials and methods.
